IM: Our study aiming to comparing the efficacy and toxicities of chemo radiotherapy of weekly Taxol versus weekly carboplatin in locally advanced head and neck carcinoma. PATIENT AND METHODS: The study divided in two arms, paclitaxel arm; 25patients treated by weekly paclitaxel 40mg/m2 with radiotherapy and carboplatin arm; 25 patients treated by weekly 150 mg carboplatin with radiotherapy. The three-dimensional radiotherapy planned (3DCRT) was 65 to 70 GY and 1.8 -2 GY /fraction, 5 fractions/week in 6-7 weeks. RESULTS: There was an insignificant 5-year disease free survival was 79.5% in carboplatin arm versus 84.6% in paclitaxel arm and 5-year OS was an insignificant 76% in carboplatin arm versus 72% in paclitaxel arm (p-value=0.646) . A 44% of both arms had overall complete remission. A 16% of patients received carboplatin had grade III/IV mucositis. Patients in paclitaxel arm had more grade II neuropathy (60%). A comparable rate of neutropenia had occurred in both arms. CONCLUSION: Both arms of concurrent chemo radiotherapy had acceptable toxicities with good quality of life response to treatment where 44% of both arms had complete response (pvalue=0.623). There was an insignificant 5-year disease free survival was 79.5% in carboplatin arm versus 84.6% in paclitaxel arm and 5-year OS was an insignificant 76% in carboplatin arm versus 72% in paclitaxel arm (p-value=0.646).